Cargando…

Tri-partite complex for axonal transport drug delivery achieves pharmacological effect

BACKGROUND: Targeted delivery of pharmaceutical agents into selected populations of CNS (Central Nervous System) neurons is an extremely compelling goal. Currently, systemic methods are generally used for delivery of pain medications, anti-virals for treatment of dermatomal infections, anti-spasmodi...

Descripción completa

Detalles Bibliográficos
Autores principales: Filler, Aaron G, Whiteside, Garth T, Bacon, Mark, Frederickson, Martyn, Howe, Franklyn A, Rabinowitz, Miri D, Sokoloff, Alan J, Deacon, Terrence W, Abell, Chris, Munglani, Raj, Griffiths, John R, Bell, B Anthony, Lever, Andrew ML
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837052/
https://www.ncbi.nlm.nih.gov/pubmed/20085661
http://dx.doi.org/10.1186/1471-2202-11-8
_version_ 1782178769027465216
author Filler, Aaron G
Whiteside, Garth T
Bacon, Mark
Frederickson, Martyn
Howe, Franklyn A
Rabinowitz, Miri D
Sokoloff, Alan J
Deacon, Terrence W
Abell, Chris
Munglani, Raj
Griffiths, John R
Bell, B Anthony
Lever, Andrew ML
author_facet Filler, Aaron G
Whiteside, Garth T
Bacon, Mark
Frederickson, Martyn
Howe, Franklyn A
Rabinowitz, Miri D
Sokoloff, Alan J
Deacon, Terrence W
Abell, Chris
Munglani, Raj
Griffiths, John R
Bell, B Anthony
Lever, Andrew ML
author_sort Filler, Aaron G
collection PubMed
description BACKGROUND: Targeted delivery of pharmaceutical agents into selected populations of CNS (Central Nervous System) neurons is an extremely compelling goal. Currently, systemic methods are generally used for delivery of pain medications, anti-virals for treatment of dermatomal infections, anti-spasmodics, and neuroprotectants. Systemic side effects or undesirable effects on parts of the CNS that are not involved in the pathology limit efficacy and limit clinical utility for many classes of pharmaceuticals. Axonal transport from the periphery offers a possible selective route, but there has been little progress towards design of agents that can accomplish targeted delivery via this intraneural route. To achieve this goal, we developed a tripartite molecular construction concept involving an axonal transport facilitator molecule, a polymer linker, and a large number of drug molecules conjugated to the linker, then sought to evaluate its neurobiology and pharmacological behavior. RESULTS: We developed chemical synthesis methodologies for assembling these tripartite complexes using a variety of axonal transport facilitators including nerve growth factor, wheat germ agglutinin, and synthetic facilitators derived from phage display work. Loading of up to 100 drug molecules per complex was achieved. Conjugation methods were used that allowed the drugs to be released in active form inside the cell body after transport. Intramuscular and intradermal injection proved effective for introducing pharmacologically effective doses into selected populations of CNS neurons. Pharmacological efficacy with gabapentin in a paw withdrawal latency model revealed a ten fold increase in half life and a 300 fold decrease in necessary dose relative to systemic administration for gabapentin when the drug was delivered by axonal transport using the tripartite vehicle. CONCLUSION: Specific targeting of selected subpopulations of CNS neurons for drug delivery by axonal transport holds great promise. The data shown here provide a basic framework for the intraneural pharmacology of this tripartite complex. The pharmacologically efficacious drug delivery demonstrated here verify the fundamental feasibility of using axonal transport for targeted drug delivery.
format Text
id pubmed-2837052
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28370522010-03-12 Tri-partite complex for axonal transport drug delivery achieves pharmacological effect Filler, Aaron G Whiteside, Garth T Bacon, Mark Frederickson, Martyn Howe, Franklyn A Rabinowitz, Miri D Sokoloff, Alan J Deacon, Terrence W Abell, Chris Munglani, Raj Griffiths, John R Bell, B Anthony Lever, Andrew ML BMC Neurosci Research article BACKGROUND: Targeted delivery of pharmaceutical agents into selected populations of CNS (Central Nervous System) neurons is an extremely compelling goal. Currently, systemic methods are generally used for delivery of pain medications, anti-virals for treatment of dermatomal infections, anti-spasmodics, and neuroprotectants. Systemic side effects or undesirable effects on parts of the CNS that are not involved in the pathology limit efficacy and limit clinical utility for many classes of pharmaceuticals. Axonal transport from the periphery offers a possible selective route, but there has been little progress towards design of agents that can accomplish targeted delivery via this intraneural route. To achieve this goal, we developed a tripartite molecular construction concept involving an axonal transport facilitator molecule, a polymer linker, and a large number of drug molecules conjugated to the linker, then sought to evaluate its neurobiology and pharmacological behavior. RESULTS: We developed chemical synthesis methodologies for assembling these tripartite complexes using a variety of axonal transport facilitators including nerve growth factor, wheat germ agglutinin, and synthetic facilitators derived from phage display work. Loading of up to 100 drug molecules per complex was achieved. Conjugation methods were used that allowed the drugs to be released in active form inside the cell body after transport. Intramuscular and intradermal injection proved effective for introducing pharmacologically effective doses into selected populations of CNS neurons. Pharmacological efficacy with gabapentin in a paw withdrawal latency model revealed a ten fold increase in half life and a 300 fold decrease in necessary dose relative to systemic administration for gabapentin when the drug was delivered by axonal transport using the tripartite vehicle. CONCLUSION: Specific targeting of selected subpopulations of CNS neurons for drug delivery by axonal transport holds great promise. The data shown here provide a basic framework for the intraneural pharmacology of this tripartite complex. The pharmacologically efficacious drug delivery demonstrated here verify the fundamental feasibility of using axonal transport for targeted drug delivery. BioMed Central 2010-01-20 /pmc/articles/PMC2837052/ /pubmed/20085661 http://dx.doi.org/10.1186/1471-2202-11-8 Text en Copyright ©2010 Filler et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
Filler, Aaron G
Whiteside, Garth T
Bacon, Mark
Frederickson, Martyn
Howe, Franklyn A
Rabinowitz, Miri D
Sokoloff, Alan J
Deacon, Terrence W
Abell, Chris
Munglani, Raj
Griffiths, John R
Bell, B Anthony
Lever, Andrew ML
Tri-partite complex for axonal transport drug delivery achieves pharmacological effect
title Tri-partite complex for axonal transport drug delivery achieves pharmacological effect
title_full Tri-partite complex for axonal transport drug delivery achieves pharmacological effect
title_fullStr Tri-partite complex for axonal transport drug delivery achieves pharmacological effect
title_full_unstemmed Tri-partite complex for axonal transport drug delivery achieves pharmacological effect
title_short Tri-partite complex for axonal transport drug delivery achieves pharmacological effect
title_sort tri-partite complex for axonal transport drug delivery achieves pharmacological effect
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837052/
https://www.ncbi.nlm.nih.gov/pubmed/20085661
http://dx.doi.org/10.1186/1471-2202-11-8
work_keys_str_mv AT filleraarong tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT whitesidegartht tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT baconmark tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT fredericksonmartyn tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT howefranklyna tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT rabinowitzmirid tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT sokoloffalanj tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT deaconterrencew tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT abellchris tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT munglaniraj tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT griffithsjohnr tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT bellbanthony tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect
AT leverandrewml tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect